Outpatient treatment of acute venous thromboembolic disease

Clinics in Chest Medicine

Volumn 24, Issue 1, 2003, Pages 49-61

  Yusen, Roger D ^a,b   Gage, Brian F ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ACUTE DISEASE; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HOME CARE; HUMAN; LENGTH OF STAY; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS; VENA CAVA FILTER;

EID: 0037346135     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00071-0     Document Type: Review

References (64)

1. Hyers T, Agnelli G, Hull R, Morris T, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93S.
2. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Wietz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J. Med 1996;334: 677-81.
3. Koopman M, Prandoni P, Piovella F, Ockelford P, Brandjes D, Van Der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
4. Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-62.
5. Belcaro G, Nicolaides A, Cesarone M, Laurora G, De Sanctis M, Incandela L, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50: 781-7.
6. Boccalon H, Elias A, Chale J, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin. Arch Intern Med 2000; 160:1769-73.
7. Wells P, Kovacs M, Bormanis J, Forgie M, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin. Arch Intern Med 1998;158:1809-12.
8. Kovacs M, Anderson D, Morrow B, Gray L, Touchie D, Wells P. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83:209-11.
9. Brandjes D, Heijboer H, Buller H, De Rijk M, Jagt H, Ten Cate J. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
10. Hull RD, Raskob GE, Rosenbloom D, Panju A, Brill-Edwards P, Ginsberg J, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
11. White R, Zhou H, Romano P. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 1998;158:1005-10.
12. Decousus H, Leizorovics A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-15.
13. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985;54:813-7.
14. Holm H, Ly B, Handeland G, Abildgaard U, Arnesen K, Gottschalk P, et al. Subcutaneous treatment of deep venous thrombosis: a comparison of unfractionated heparin and low molecular weight heparin. Haemostasis 1986;16:30S-7S.
15. Albada J, Niewwenhuis H, Sixma J. Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin): results of a double-blind randomized study. Circulation 1989;80:935-40.
16. Duroux P, Beclere A. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991;65:251-6.
17. Hull R, Raskob G, Pineo G, Green D, Trowbridge A, Elliot G, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-82.
18. Prandoni P, Lensing A, Buller H, Carta M, Cogo A, Vigo M, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339:441-5.
19. Holmström M, Berglund C, Granquist S, Bratt G, Tomebotim E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992;67:49-55.
20. Lopaciuk S, Meissner A, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992;68:14-8.
21. Simonneau G, Charbonnie B, Decousus H, Planchon B, Ninet J, Sic P, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153: 1541-6.
22. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
23. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to Coumarin. Thromb Haemost 1994;71:7-11.
24. Alhenc-Gelas M, Jestin-Le Guemic C, Vitoux J, Kher A, Alach M, Fiessinger J. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
25. Fiessinger J, Lopez-Femandez M, Gatterer E, Granqvist S, Kher A. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76:195-9.
26. Charbonnier B, Fiessinger J, Banga J, Wenzel E, d'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 1998;79:897-901.
27. Merli G, Spiro T, Olsson C, Abilgaard U, Davidson B, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
28. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban J, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337:663-9.
29. Gould M, Dembitzer A, Doyle R, Hastie T, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
30. Dolovich L, Ginsberg J, Douketis J, Holbrook A, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000;160:181-8.
31. Rocha E, Martinez-Gonzalez M, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85:935-42.
32. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med 1996;240:395-401.
33. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Health Syst Pharm 1997;54: 1968-72.
34. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158:2001-3.
35. Goldhaber S, Morrison R, Diran L, Creager M, Lee T. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. Arch Intern Med 1998; 158:2325-8.
36. Ting S, Ziegenbein R, Gan T, Catalano J, Monagle P, Silvers J, et al. Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med J Australia 1998;168:272-6.
37. Mattiasson I, Berntorp E, Bornhov S, Lagerstedt C, Lethagen S, Persson J, et al. Outpatient treatment of acute deep vein thrombosis. Int Angiol 1998;17:146-50.
38. O'Shaughnessy D, Tovey C, Miller A, O'Neill V, Rana P, Akbar S, et al. Outpatient management of deep vein thrombosis. J Accid Emerg Med 1998;15:292-3.
39. Pearson S, Blair R, Halper A, Eddy E, McKean S. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin. Effective Clinical Practice 1999;2:210-7.
40. Blättler W, Kreis N, Blattler I. Practicability and quality of outpatient management of acute deep venous thrombosis. J Vasc Surg 2000;32:855-60.
41. Dunn A, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks H, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110:458-62.
42. Grau E, Tenias J, Real E, Medrano J, Ferrer R, Pastor E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: long-term incidence of recurrent venous thromboembolism. Am J Hematol 2001;67:10-4.
43. Vinson D, Berman D. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. Ann Emerg Med 2001;37:251-8.
44. Douketis J, Foster G, Crowther M, Prins M, Ginsberg J. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160:3431-6.
45. de Lissovoy G, Yusen R, Spiro T, Krupski W, Champion A, Sorensen S. Cost for inpatient care of venous thrombosis - a trial of enoxaparin vs standard heparin. Arch Intern Med 2000;160:3160-5.
46. Gould M, Dembitzer A, Sanders G, Garber A. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
47. Spyropoulos A, Hurley J, Ciesla G, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108-14.
48. Hull R, Raskob G, Rosenbloom D, et al. Low-molecular-weight heparin was more cost-effective than intravenous heparin for treating proximal venous thrombosis. Arch Intern Med 1997;157:289-94.
49. van den Belt A, Bossuyt P, Prins M, Gallus A, Buller H. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. Thromb Haemost 1998;79:259-63.
50. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159: 2298-304.
51. Tillman D, Charland S, Witt D. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32.
52. Huse D, Communis G, Taylor D, Russell M. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Am J Manag Care 2002;8:S10-6.
53. Rodger M, Bredeson C, Wells P, Beck J, Keams B, Huebsch L. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998;159:931-8.
54. Bossuyt P, van den Belt A, Prins M. Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life. Haemostasis 1998; 28:100-7.
55. Smith B, Weekley J, Pilotto L, Howe T, Beven R. Cost comparison of at-home treatment of deep vein thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. Int Med J 2002; 32:29-34.
56. Douketis J, Kearon C, Bates S, Duku E, Ginsberg J. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279: 458-62.
57. Yusen R, Haraden B, Gage B, Woodward R, Rubin B, Botney M. Criteria for outpatient management of proximal lower extremity deep venous thrombosis. Chest 1999;115:972-9.
58. Gage B, Fihn S, White R. Management and dosing of warfarin therapy. Am J Med 2000;109:481-8.
59. Harrison L, Johnston M, Massicotte M, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
60. Banet G, Waterman A, Milligan P, Gatchel S, Gage B. Warfarin dose reduction versus watchful waiting for mild elevations in the international normalized ratio. Chest 2003;123:499-503.
61. Crowther M, Douketis J, Schnurr T, Steidl L, Mera V, Ultori C, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. Ann Intern Med 2002;137:251-4.
62. Makris M, Greaves M, Phillips W, Kitchen S, Rosendaal F, Preston F. Emergency oral anticoagulation reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-80.
63. Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995;73:439-43.
64. Hansson P, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis. Arch Intern Med 2000;160:769-74.